Claude AI Takes on Drug Discovery, from Antibody Design to Clinical Trial Analysis

Anthropic is expanding its Claude AI into the pharmaceutical industry, reporting early progress in using the model to accelerate drug development across multiple stages. The company’s life sciences team detailed partnerships with six organizations, including BigHat Biosciences and Bristol Myers Squibb, and revealed that Anthropic has initiated its own drug discovery programs, such as one targeting rare childhood muscular dystrophy, according to Hacker News. "the best way to identify and work through these bottlenecks is to get deeply involved in real drug programs" TechRadar reported that Anthropic wants to use Claude to help discover new lifesaving drugs, applying the AI to drug discovery, antibody development, pharmaceutical manufacturing, and clinical research. The company noted that bottlenecks in drug R&D are scattered across target discovery, molecule design, process optimization, regulatory filings, and clinical-trial design and operations, as finance.biggo.com explained. At Divergence Labs, Claude generated approximately 35,000 antibody designs over a month for a prospective food-allergy treatment intended to remove immunoglobulin E (IgE) from immune cells, according to dig.watch. Meanwhile, Generate Biomedicines reported a 70% reduction in CAR T-cell component length, and modified immune cells produced roughly ten times more cancer-detecting receptors, as dumpsterfire.com noted. Bristol Myers Squibb is using Claude to assess plans of an early-stage drug in clinical trials and to estimate the likelihood of those trials succeeding, hpcwire.com reported. Together, the companies plan to expand this work in 2027 to understand its potential for increasing the efficiency of clinical development. Anthropic also acquired a one-person pharmaceutical startup as part of its AI R&D bet, finance.biggo.com added, signaling a deeper commitment to embedding Claude directly into the drug development pipeline.

6 sources•2 NovRead the Baker's Take→